CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients (Q42479947)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 16, 2010

Language	Label	Description	Also known as
English	CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients	scientific article published on November 16, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

1 reference

based on heuristic

inferred from title

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

neoplastic gene expression regulation

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21080107

27 August 2024

author name string

Xi-ru Li

1

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Mei Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Yan-jun Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Jian-dong Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Yi-qiong Zheng

5

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Jie Li

6

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Bing Ma

7

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Xin Song

8

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21080107

27 August 2024

publication date

16 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

full work available at URL

http://link.springer.com/content/pdf/10.1007/s12032-010-9742-6.pdf

Portable Document Format

1 reference

10.1007/S12032-010-9742-6

https://api.crossref.org/works/10.1007/S12032-010-9742-6

27 August 2024

http://link.springer.com/article/10.1007/s12032-010-9742-6/fulltext.html

1 reference

10.1007/S12032-010-9742-6

https://api.crossref.org/works/10.1007/S12032-010-9742-6

27 August 2024

http://link.springer.com/content/pdf/10.1007/s12032-010-9742-6

1 reference

10.1007/S12032-010-9742-6

https://api.crossref.org/works/10.1007/S12032-010-9742-6

27 August 2024

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

28 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

S129-34

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na(+), K(+)-ATPase

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9742-6

21 January 2018

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein Markers in Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21080107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-010-9742-6

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42479947&oldid=2237665810"